▁to ▁develop ▁resistance . ▁The ▁In fect ious ▁D ise ase ▁Society ▁of ▁America ▁report ▁noted ▁that ▁the ▁number ▁of ▁new ▁ant ib iot ics ▁approved ▁for ▁market ing ▁per ▁year ▁had ▁been ▁decl ining ▁and ▁identified ▁seven ▁ant ib iot ics ▁against ▁the ▁Gram - negative ▁b ac illi ▁currently ▁in ▁phase ▁ 2 ▁or ▁phase ▁ 3 ▁clin ical ▁tri als . ▁However , ▁these ▁dru gs ▁did ▁not ▁address ▁the ▁entire ▁spectrum ▁of ▁resistance ▁of ▁Gram - negative ▁b ac illi . ▁According ▁to ▁the ▁W HO ▁fifty ▁one ▁new ▁th era pe ut ic ▁entities ▁- ▁ant ib iot ics ▁( including ▁combinations ), ▁are ▁in ▁phase ▁ 1 - 3 ▁clin ical ▁tri als ▁as ▁of ▁May ▁ 2 0 1 7 . ▁Rec ent ▁entries ▁in ▁the ▁clin ical ▁pipeline ▁target ing ▁mult id rug - res istant ▁Gram - pos itive ▁path og ens ▁has ▁improved ▁the ▁treatment ▁options ▁due ▁to ▁market ing ▁appro val ▁of ▁new ▁ant ib i otic ▁classes , ▁the ▁ox az olid in ones ▁and ▁cy clic ▁li po pe pt ides . ▁However , ▁resistance ▁to ▁these ▁ant ib iot ics ▁is ▁certainly ▁likely ▁to ▁occur , ▁the ▁need ▁for ▁the ▁development ▁new ▁ant ib iot ics ▁against ▁those ▁path og ens ▁still ▁remains ▁a ▁high ▁priority . ▁Rec ent ▁dru gs ▁in ▁development ▁that ▁target ▁Gram - negative ▁b acter ia ▁have ▁focused ▁on ▁re - working ▁existing ▁dru gs ▁to ▁target ▁specific ▁micro organ isms ▁or ▁specific ▁types